Virax Biolabs Group Limited Ordinary Shares Cash Flow Conversion Efficiency
Virax Biolabs Group Limited Ordinary Shares cash flow conversion efficiency. Based on the latest financial reports, Virax Biolabs Group Limited Ordinary Shares (VRAX) has a cash flow conversion efficiency ratio of -0.576x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.92 Million) by net assets ($5.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Virax Biolabs Group Limited Ordinary Shares (2020–2025)
Cash flow conversion efficiency of Virax Biolabs Group Limited Ordinary Shares from 2020 to 2025. This chart illustrates how Virax Biolabs Group Limited Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Virax Biolabs Group Limited Ordinary Sha for real-time trading data and today's change.
Virax Biolabs Group Limited Ordinary Shares Cash Flow Conversion Ratio Explained
Virax Biolabs Group Limited Ordinary Shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Virax Biolabs Group Limited Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Virax Biolabs Group Limited Ordinary Shares ranked by their cash flow conversion efficiency. Also see Virax Biolabs Group Limited Ordinary Sha (VRAX) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dixie Gold Inc
V:DG
|
-0.501x |
|
JZ Capital Partners Ltd
LSE:JZCP
|
0.125x |
|
MEP Infrastructure Developers Limited
NSE:MEP
|
-0.376x |
|
SIG plc
LSE:SHI
|
0.208x |
|
Atomic Minerals Corp
V:ATOM
|
-0.496x |
|
Investment Friends Capital SE
WAR:IFC
|
0.002x |
|
Barakah Offshore Petroleum Bhd
KLSE:7251
|
0.017x |
|
Peel Hunt Ltd
LSE:PEEL
|
0.134x |
Annual Cash Flow Conversion Efficiency for Virax Biolabs Group Limited Ordinary Shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Virax Biolabs Group Limited Ordinary Shares from 2020 to 2025. Review financial agility of Virax Biolabs Group Limited Ordinary Sha to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $5.46 Million | $-4.56 Million | -0.835x | +31.27% |
| 2024-03-31 | $5.14 Million | $-6.25 Million | -1.216x | -158.97% |
| 2023-03-31 | $8.90 Million | $-4.18 Million | -0.469x | -169.43% |
| 2022-03-31 | $-1.20 Million | $-809.07K | 0.676x | -10.96% |
| 2021-03-31 | $-777.32K | $-590.19K | 0.759x | +23.90% |
| 2020-03-31 | $-1.22 Million | $-744.61K | 0.613x | -- |
About Virax Biolabs Group Limited Ordinary Shares
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, ot… Read more